ASML's planned 2027-28 output cannot meet customer demand, supporting a Buy rating and €1,830 target. Long-term customer down payments rose from €3.6bn to €9.3bn; customers seek 2029-30 orders that ASML has not accepted. Critical-tool price rises begin in 2027, with full effect in 2028, but are not meant to recur annually. Q3 EPS excluding a €509.7m investment gain still beat consensus. x.com  x.com  x.com  x.com  x.com 

ASML looks undervalued, a rare sight for this company, because its long-term AI opportunity is much bigger than the market is pricing in. AI is driving demand for advanced logic and memory chips, customers are accelerating capacity expansion, and ASML sits right in the middle of that buildout. Q2 revenue reached €9.3B with €2.9B in net income, and management raised its 2026 revenue outlook to €43B-€45B. x.com  x.com 

ASML may have topped, since semicap thrives on shortage and would be hit hardest in an overbuild. Then earnings acceleration from memory and fab projects stops or reverses; the labs' leading-edge chase may be at its apex, positioning is bullish and the moat is threatened. Bullishness on Korean, US and Taiwan fab projects makes sense for now. But if the cycle top is confirmed and labs change how they chase the frontier, or token deflation kills some labs, the shortage can end sooner. x.com  x.com  … Show more

ASML's reported inability to make enough machines for the next two years is a buy signal for the whole AI stack. Its stock still sold off despite that shortage. x.com 

AI demand is benefiting ASML's lithography-machine business immensely. It could be the widest-moat company ever, and analysts expect revenue to rise 50% and earnings 94% ahead of its report. x.com 

ASML lacks the growth it needs, even though @mzuhair123 makes a good case that High-NA going mainstream by decade-end will strengthen its Dutch hegemony. x.com 

ASML's tightened sales guidance raises the floor for its growth outlook as management has become more confident in this year's forecast. Analyst targets imply 35.7% upside from here. x.com 

ASML's EUV R&D is starting to pay off through operating leverage. Q3 R&D fell as a share of sales, though one quarter is not a trend. Higher units, IBM sales and EUV/DUV prices put 2028 estimates well above the 2030 guide and ahead of consensus; shares look cheap at €1,530. Assuming 30% prepayment, liabilities imply €42-45bn of orders in 2026's first nine months, subject to invoicing lags. The proposed MATCH Act could restrict China sales; 2029-30 demand is less certain than 2028. x.com  x.com  … Show more

ASML's valuation does not make sense at 45-50x forward earnings unless estimates are too low by around 2x. It has always had pricing power but chosen not to exercise it; that may change, but if it does not, the multiple is hard to justify relative to other opportunities. x.com  x.com 

ASML cannot make enough EUV machines to meet demand, which it says will outrun supply through 2028. Its 2026 sales guide rose from €34-39 billion to €44-45 billion, and gross margin hit 57.5%. The combination of an EUV monopoly, demand outrunning supply and growing pricing power is rare. x.com